Pharmacia & Upjohn Aromasin
Executive Summary
Exemestane tablets approved Oct. 21 for the treatment of advanced breast cancer in patients "whose tumors stop responding to tamoxifen." Aromasin demonstrated a superior median time to tumor progression (20.3 weeks vs. 16.6 weeks) and median time to treatment failure (16.3 weeks vs. 15.7 weeks), according to Phase III data presented at the American Society of Clinical Oncology annual meeting